Volume 13, Number 3—March 2007
Worldwide Emergence of Extensively Drug-resistant Tuberculosis
|Geographic region||Total no. isolates tested†||Total MDR-TB patients||Total XDR-TB patients|
|N||n (% of all isolates tested)||n (% of MDR-TB patients)|
|Industrialized nations‡||2,499||821 (32.9)||53 (6.5)|
|Latin America§||985||543 (55.1)||32 (5.9)|
|Eastern Europe¶ and Russia||1,153||406 (35.2)||55 (13.6)|
|Africa and Middle East#||665||156 (23.5)||1 (0.6)|
|Asia (other than Republic of Korea)***||391||274 (70.1)||4 (1.5)|
|Republic of Korea||11,939||1,298 (10.9)||200 (15.4)|
*Region from which isolate was submitted to Supranational Reference Laboratory. MDR-TB, multidrug-resistant tuberculosis; XDR-TB, extensively drug-resistant tuberculosis, i.e., multidrug-resistant tuberculosis (resistant to at least isoniazid and rifampin) with additional resistance to ≥3 classes of second-line drugs.
†Total no. of isolates tested for resistance to >3 second-line drug classes, including aminoglycosides (amikacin or kanamycin), polypeptides (capreomycin), fluoroquinolones (ofloxacin or ciprofloxacin), thioamides (ethionamide or prothionamide), cycloserine, and para-aminosalicyclic acid.
‡United States, Canada, United Kingdom, countries in Western Europe (Ireland, Portugal, Germany, France, Belgium, Spain), Japan, and Australia.
§Argentina, Bolivia, Brazil, Chile, Ecuador, Guyana, French Guiana, Peru, Mexico, Guatemala, El Salvador, Costa Rica.
¶Republic of Georgia, Czech Republic, Azerbaijan, Armenia.
#Afghanistan, Algeria, Egypt, Tunisia, Botswana, Burundi, Cameroon, Central African Republic, Côte d’Ivoire, Djibouti, Madagascar, Rwanda, South Africa, Senegal, Uganda.
**Bangladesh, Indonesia, Papua New Guinea, Thailand, East Timor.
††For 2 XDR-TB patients, data were missing about geographic region.